Evidence map›Paper›PMID 42377399›Full record

ArticleMolecular biology reports2026

The interplay of bosentan and finerenone in amelioration of cardiac dysfunction within benign prostatic hyperplasia in rats.

Marwa Monier Mahmoud Refaie, Asmaa A Hasan, Asmaa A Muhammed, Randa Ahmed Ibrahim, Eman Abdel Naby Hassan, Enas Fathy, Aml Mohamed Soliman, Hoda S Sherkawy, Olivia N Beshay, Amr Alam-Eldin Ahmed and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Marwa Monier Mahmoud RefaieDepartment of Medical Pharmacology, Faculty of Medicine, Minia University, 61511, Minia, Egypt.
Asmaa A HasanDepartment of Human Anatomy and Embryology, Faculty of Medicine, Aswan University, 81528, Aswan, Egypt. asmaa.elsaid@aswu.edu.eg.ORCID http://orcid.org/0009-0009-3787-1823
Asmaa A MuhammedDepartment of Medical Physiology, Faculty of Medicine, Aswan University, 81528, Aswan, Egypt.
Randa Ahmed IbrahimDepartment of Histology and Cell Biology, Faculty of Medicine, Minia University, 61511, Minia, Egypt.
Eman Abdel Naby HassanDepartment of Internal medicine, Faculty of Medicine, Minia University, 61511, Minia, Egypt.
Enas FathyDepartment of cardiology, Faculty of Medicine, Aswan University, 81528, Aswan, Egypt.
Aml Mohamed SolimanDepartment of cardiology, Faculty of Medicine, Aswan University, 81528, Aswan, Egypt.
Hoda S SherkawyDepartment of Medical Biochemistry, Faculty of Medicine, Aswan University, 81528, Aswan, Egypt.
Olivia N BeshayDepartment of Biochemistry, Faculty of Pharmacy, Minia University, 61511, Minia, Egypt.
Amr Alam-Eldin AhmedDepartment of Urology, Faculty of Medicine, Aswan University, 81528, Aswan, Egypt.
Ahmed AhmedDepartment of Urology, Faculty of Medicine, Aswan University, 81528, Aswan, Egypt.
Samar Hisham ElsayedDepartment of Medical Biochemistry, Faculty of Medicine, Minia University, 61511, Minia, Egypt.
Heba A HabibDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, 61511, Minia, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesBenign prostatic hyperplasia (BPH) is a widespread urological clinical case in aged men associated with troublesome lower urinary tract symptoms and cardiac dysfunction, but its medical treatment is still insufficient. Thus, searching for more effective medical regimens is an essential target. We tried in current experiment to explore the role of bosentan (BOS) and/or finerenone (FIN) in this lesion.

methodsBPH was adequately induced using testosterone propionate (TP) in a dose of (5 mg/kg/day) for 28 days of subcutaneous injection and an oral administration of BOS (50 mg/kg/day) and/or FIN (10 mg/kg/day) for 10 days.

resultsWe found typical histopathological changes of BPH, increased serum dihydrotestosterone (DHT), prostatic specific antigen (PSA), cardiac enzymes, tissue malondialdehyde (MDA), aldosterone, endothelin-A, nuclear factor kappa b (NF-κB), and proliferating cell nuclear antigen (PCNA). However, significant decreases in total antioxidant capacity (TAC), reduced glutathione (GSH), and caspase-3. The histological findings were augmented by special staining techniques, immunohistochemical and morphometric studies. There are histopathological alternations as the hyperplastic nodules in the prostate's transition zone expand, and the prostatic urethra was compressed, lengthened and distorted. Interestingly the co-administration of BOS and/or FIN significantly improved BPH induced changes. This is mostly attributed to its ability in modulating endothelin receptors by BOS, aldosterone receptors by FIN, improved the histopathological changes with anti-oxidant, anti-inflammatory, anti-fibrotic, antiproliferative, and apoptotic properties.

conclusionsBOS and/or FIN showed a significant ameliorative effect in BPH.

Indexed as

BosentanProstatic HyperplasiaAnimalsDihydrotestosteroneMaleMalondialdehydeNF-kappa BOxidative StressProliferating Cell Nuclear AntigenProstateProstate-Specific AntigenRatsRats, WistarTestosterone PropionateBosentanDihydrotestosteroneMalondialdehydeNF-kappa BProliferating Cell Nuclear AntigenProstate-Specific AntigenTestosterone PropionateBenign prostatic hyperplasiaBosentanFinerenoneProliferating cell nuclear antigenProstatic specific antigen

Identifiers

PMID42377399

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.